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Summary
Background In 2010 a new diagnostic test for tuberculosis, Xpert MTB/RIF, received a conditional programmatic 
recommendation from WHO. Several model-based economic evaluations predicted that Xpert would be cost-effective 
across sub-Saharan Africa. We investigated the cost-effectiveness of Xpert in the real world during national roll-out in 
South Africa.
Methods For this real-world cost analysis and economic evaluation, we applied extensive primary cost and patient 
event data from the XTEND study, a pragmatic trial examining Xpert introduction for people investigated for 
tuberculosis in 40 primary health facilities (20 clusters) in South Africa enrolled between June 8, and Nov 16, 2012, to 
estimate the costs and cost per disability-adjusted life-year averted of introducing Xpert as the initial diagnostic test 
for tuberculosis, compared with sputum smear microscopy (the standard of care).
Findings The mean total cost per study participant for tuberculosis investigation and treatment was US$312·58 
(95% CI 252·46–372·70) in the Xpert group and $298·58 (246·35–350·82) in the microscopy group. The mean 
health service (provider) cost per study participant was $168·79 (149·16–188·42) for the Xpert group and $160·46 
(143·24–177·68) for the microscopy group of the study. Considering uncertainty in both cost and effect using a wide 
range of willingness to pay thresholds, we found less than 3% probability that Xpert introduction improved the cost-
effectiveness of tuberculosis diagnostics.
Interpretation After analysing extensive primary data collection during roll-out, we found that Xpert introduction in 
South Africa was cost-neutral, but found no evidence that Xpert improved the cost-effectiveness of tuberculosis 
diagnosis. Our study highlights the importance of considering implementation constraints, when predicting and 
evaluating the cost-effectiveness of new tuberculosis diagnostics in South Africa.
Funding Bill & Melinda Gates Foundation.
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Introduction
In 2014, 1·5 million people died from tuberculosis, of 
whom 25% had HIV and 13% had multidrug-resistant 
tuberculosis.1 Correctly identifying tuberculosis in a 
timely manner remains a central programmatic 
challenge. The diagnosis of tuberculosis in most settings 
with a high tuberculosis burden is based on sputum 
smear microscopy. Sputum smear microscopy has a 
limited sensitivity, especially in people living with HIV/
AIDS, and cannot distinguish multidrug-resistant 
tuberculosis.2 This poor performance, together with 
inadequate access to laboratory facilities in many low-
income and middle-income countries, contributes to low 
levels of tuberculosis case detection globally, particularly 
in countries with a high prevalence of HIV. In 2010, a new 
test, Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA), 
received a guideline recommendation from WHO for use 
as an initial diagnostic test for tuberculosis.3 A Cochrane 
systematic review4 found that Xpert has a specificity of 
98% and a sensitivity of 88%, and has 80% sensitivity for 
people living with HIV, compared with the gold standard 
of culture. Xpert also provides a signal for rifampicin-
resistant tuberculosis, a marker for multidrug-resistant 
tuberculosis. Since the development of Xpert, several 
other new tuberculosis diagnostic technologies have 
emerged or are anticipated in the coming years.
Many model-based economic evaluations,5–7 predicted 
that Xpert would be cost-effective, either through a 
reduction in tuberculosis-related mortality or reduction in 
the overtreatment of tuberculosis, or both, in a wide range 
of settings. Nevertheless, concerns over cost-effectiveness 
remained and the WHO guideline recommendation 
was conditional, explicitly acknowledging potential 
resource implications. An individually randomised 
clinical trial (TB-NEAT)8 suggested that high levels of 
tuberculosis treatment without bacteriological 
confirmation (ie, empirical treatment) might result in 
Xpert having a limited effect on tuberculosis-related 
mortality in practice in South Africa.9 Applying these 
results to their original model, Menzies and colleagues9 
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found Xpert would still be cost-effective, partly due to a 
reduction in treatment costs, although cost-effectiveness 
was reduced from earlier estimates.
In 2012, the decision was made to rapidly roll out Xpert 
in South Africa at scale.10 The National Department of 
Health, South Africa agreed to stage the roll-out of Xpert 
to allow for a pragmatic cluster-randomised trial, the 
XTEND study,11 to assess the effect on mortality and cost-
effectiveness of Xpert’s introduction across South Africa. 
The XTEND study found no evidence that the Xpert 
introduction reduced 6 month mortality risk in adult 
clinic attendees being investigated for tuberculosis11 as 
Xpert was scaled up nationally. We present a cost analysis 
and economic evaluation comparing Xpert with sputum 
smear microscopy as an initial diagnosis for tuberculosis. 
We analysed an extensive set of primary data, which was 
collected as Xpert was rolled out in South Africa, to 
estimate real-world costs and cost-effectiveness. In doing 
so, we aimed to improve the existing economic analysis 
used to inform investment in tuberculosis diagnostics.
Methods
Study design and participants
For this real-world cost analysis and economic evaluation, 
we analysed data collected from 40 primary health facilities 
during the XTEND study,11 a pragmatic cluster-randomised 
trial, in which 20 clusters (defined as laboratories) in 
four provinces in South Africa (Gauteng, Mpumalanga, 
Free State, and Eastern Cape) were randomly assigned into 
Xpert or sputum smear microscopy groups, stratified by 
province. At two primary care clinics per laboratory, a 
systematic sample of adults aged 18 years or older and 
systematically selected by health service staff as needing to 
provide sputum for tuberculosis investigation were 
enrolled. 4972 people were screened for study inclusion, 
and 4656 (94%) were enrolled and followed up for 6 months 
(median age 36 years; 2891 [62%] of 4656 were female; 
2206 [62%] of 3542 who were tested and willing to share 
results reported being HIV-positive). The Xpert group were 
less likely to have a body-mass index of less than 18·5 kg/m² 
and to report tuberculosis symptoms.11 Further details of 
the study population can be found in the appendix.
Participants of the XTEND study were enrolled between 
June 8, and Nov 16, 2012, and follow-up ended on May 17, 
2013. The timeframe for our economic analysis and cost 
data collection was within trial from enrolment until the 
6 month follow-up interview. This timeframe excludes 
three factors that potentially could affect cost-effectiveness 
after the 6 month follow-up. First, by reducing time with 
tuberculosis, Xpert might reduce the transmission of 
tuberculosis. However, the XTEND study11 found no 
evidence for differences in time to treatment, the factor 
most likely to affect transmission. Second, increased 
diagnosis and survival from tuberculosis might increase 
antiretroviral therapy costs. However, no increase in the 
number of people initiating antiretroviral therapy was 
reported during XTEND. Third, and most importantly, 
XTEND might improve outcomes by hastening the time 
to effective treatment in people with multidrug-resistant 
tuberculosis. XTEND was not powered to examine 
differences in time to multidrug-resistant tuberculosis 
treatment initiations; as such, the study provides no new 
evidence on the effect of Xpert on the treatment and 
outcomes of people with multidrug-resistant tuberculosis. 
However, intuitively, the identification of rifampicin 
resistance might improve the time to treatment of people 
with multidrug-resistant tuberculosis; consequently, 
previous economic evaluations use models to investigate 
the potential for Xpert to improve outcomes over a period 
longer than 6 months.
Research in context
Evidence before this study
We searched PubMed for studies published in English between 
Jan 1, 2010, and June 30, 2016, using the terms “tuberculosis” 
AND “cost” AND (“Xpert*” OR “Genexpert” OR “MTB/RIF”). 
Several previous studies have been done to estimate the 
cost-effectiveness of Xpert MTB/RIF using models. These studies 
all found Xpert MTB/RIF to be cost-effective, with the most 
recent study estimating incremental cost per disability-adjusted 
life-year (DALY) averted at US$1208 (95% posterior intervals 
621–3995) in South Africa. No previous studies were found that 
assessed the cost-effectiveness of Xpert MTB/RIF (in terms of 
cost per DALY averted) using primary data on costs and 
outcomes in routine settings.
Added value of this study
This study provides robust evidence that suggests Xpert MTB/
RIF did not increase the costs or improve the cost-effectiveness 
of tuberculosis investigation, diagnosis, and treatment in the 
context of routine implementation in South Africa, for a cohort 
of people being investigated for tuberculosis. The study 
provides an illustration of the potential effect of real-world 
implementation on estimates of the cost-effectiveness of new 
diagnostics.
Implications of all the available evidence
While new tuberculosis diagnostics continue to offer substantial 
potential, this study, along with other research from South Africa 
and Brazil, suggests that the incremental costs, effect, and 
cost-effectiveness of Xpert MTB/RIF might be fundamentally 
affected by real-world issues such as empirical treatment 
practices, availability of HIV treatment, and provider and patient 
adherence. We recommend that future investments in 
tuberculosis diagnostics (and the analysis used to inform them) 
should explicitly consider and reflect uncertainty (and the 
additional costs) of implementation constraints, the tuberculosis 
cascade, and the availability of complementary interventions.
See Online for appendix
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We examined the emerging evidence from the Xpert 
roll-out in South Africa to ascertain whether the inclusion 
of these potential outcomes occurring later than 6 months 
in our analysis was justified. Some evidence suggests that 
Xpert might reduce time to multidrug-resistant 
tuberculosis treatment by around 3 weeks.12 A 2017 
retrospective cohort study13 of the pathways to treatment 
of patients with multidrug-resistant tuberculosis (done at 
the same time as XTEND) suggests a reduction in the 
time to treatment of around 17 days; however, the authors 
found no difference in the proportions of patients who 
initiated treatment before 6 months, between patients 
diagnosed with Xpert compared with patients diagnosed 
with other methods, and did not follow-up the cohort to 
measure outcomes. Because of the inconclusive nature of 
this evidence and because we aimed to assess real-world 
cost-effectiveness with an empirical approach, we did not 
include any additional effect on multidrug-resistant 
tuberculosis in our estimates.
We were guided in our analytical approach by the 
reference case developed by the Methods for Economic 
Evaluation Project (MEEP).14 A full methodological 
description of the study according to the MEEP reference 
case can be found in the appendix. Our approach also 
reflects the economic school of thought that, even when 
trial results find no significant evidence of an effect, a full 
cost-effectiveness analysis should be done, presenting all 
uncertainty in both costs and effects15 before concluding 
on cost-effectiveness.
We did comparative cost and cost-effectiveness analyses 
of Xpert versus the standard of care, sputum smear 
microscopy. From a societal perspective, we compared the 
cost per person investigated for tuberculosis and the cost 
per disability-adjusted life-year (DALY) averted. The 
Sputum smear microscopy group (n=2332) Xpert group (n=2324)
Initial 
positive 
tuberculosis 
test result
Initial negative 
tuberculosis 
test result, 
followed up 
with radiograph 
or culture
Initial negative 
tuberculosis test 
result with no 
follow-up with 
radiograph or 
culture
Initial 
tuberculosis 
test result 
unknown
Total Initial 
positive 
tuberculosis 
test result
Initial negative 
tuberculosis 
test result, 
followed up 
with radiograph 
or culture
Initial negative 
tuberculosis 
test result with 
no follow-up 
with radiograph 
or culture
Initial 
tuberculosis 
test result 
unknown
Total
People investigated for 
tuberculosis
174 441 1645 72 2332 200 211 1782 131 2324
Patient events
Total nights in hospital 47 (9%) 347 (69%) 90 (18%) 22 (4%) 506 (100%) 170 (31%) 281 (51%) 42 (8%) 53 (10%) 546 (100%)
Patients on ART before 
enrolment
26 (9%) 73 (27%) 165 (60%) 11 (4%) 275 (100%) 18 (6%) 54 (18%) 201 (69%) 19 (7%) 292 (100%)
Patients starting ART after 
enrolment
35 (12%) 73 (26%) 162 (58%) 11 (4%) 281 (100%) 50 (20%) 30 (12%) 161 (64%) 11 (4%) 252 (100%)
Total health-care visits for 
tuberculosis symptoms
194 (9%) 492 (22%) 1430 (64%) 118 (5%) 2234 (100%) 315 (11%) 358 (13%) 1991 (71%) 151 (5%) 2815 (100%)
Treatment
Total treatment initiations 160 (55%) 70 (24%) 43 (15%) 18 (6%) 291 (100%) 180 (72%) 33 (13%) 21 (8%) 16 (6%) 250 (100%)
Category 1 134 (55%) 61 (25%) 36 (15%) 14 (6%) 245 (100%) 161 (72%) 31 (14%) 17 (8%) 15 (7%) 224 (100%)
Category 2 (retreatment) 19 (56%) 8 (24%) 3 (9%) 4 (12%) 34 (100%) 9 (75%) 2 (17%) 1 (8%) 0 12 (100%)
Multidrug resistant 
tuberculosis treatment
1 (33%) 1 (33%) 1 (33%) 0 3 (100%) 2 (100%) 0 0 0 2 (100%)
Other 3 (50%) 1 (17%) 2 (33%) 0 6 (100%) 4 (67%) 0 2 (33%) 0 6 (100%)
Missing 4 (80%) 0 1 (20%) 0 5 (100%) 7 (78%) 0 1 (11%) 1 (11%) 9 (100%)
Diagnostic and monitoring tests
Total chest radiographs 17 (13%) 104 (76%) 0 15 (11%) 136 (100%) 13 (9%) 116 (82%) 0 13 (9%) 142 (100%)
Total antibiotic courses 22 (5%) 107 (23%) 307 (66%) 26 (6%) 462 (100%) 76 (12%) 96 (15%) 436 (66%) 51 (8%) 659 (100%)
Total HIV tests 49 (8%) 132 (22%) 376 (63%) 37 (6%) 594 (100%) 78 (13%) 74 (13%) 392 (67%) 43 (7%) 587 (100%)
Total sputum smear 
microscopy tests (excluding 
initial test)
204 (18%) 226 (20%) 677 (59%) 35 (3%) 1142 (100%) 252 (78%) 33 (10%) 19 (6%) 19 (6%) 323 (100%)
Total Xpert tests (excluding 
initial test)
0 0 0 0 0 22 (17%) 26 (20%) 52 (40%) 31 (24%) 131 (100%)
Total cultures 82 (16%) 388 (78%) 0 27 (5%) 497 (100%) 24 (14%) 136 (81%) 0 7 (4%) 167 (100%)
Total line probe assays 69 (55%) 29 (23%) 25 (20%) 2 (2%) 125 (100%) 73 (61%) 19 (16%) 22 (18%) 5 (4%) 119 (100%)
Total drug susceptibility tests 43 (61%) 13 (19%) 10 (14%) 4 (6%) 70 (100%) 30 (50%) 10 (17%) 17 (28%) 3 (5%) 60 (100%)
ART=antiretroviral therapy.
Table 1: Total patient events reported by study group and initial tuberculosis test results
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population studied was a cohort of people being assessed 
for tuberculosis and attending primary health-care clinics 
in South Africa.
The study was approved by the research ethics 
committees of the University of Cape Town, University of 
the Witwatersrand, London School of Hygiene & Tropical 
Medicine, and WHO. Health department officials and 
facility managers provided permission to do the study in 
the selected facilities and written informed consent was 
obtained from respondents.
Study intervention and comparator
We compared the intervention, Xpert MTB/RIF, with the 
comparator, sputum smear microscopy, as initial tests for 
tuberculosis. However, both intervention and comparator 
required additional technologies for their imple-
mentation.16 Xpert required changes to the tuberculosis 
diagnostic and treatment pathways. Because Xpert 
provides a signal for rifampicin resistance, the 
retreatment tuberculosis regimen for patients who did 
not respond to first-line treatment or who have previously 
had tuberculosis treatment is no longer required. A figure 
of the sputum smear microscopy and Xpert algorithms 
studied is contained in the appendix. Additionally, the 
roll-out of Xpert required supportive activities, including 
restructuring of workloads in laboratories and quality 
control.17 Xpert roll-out commenced in March, 2011, with 
sequential capacitation of laboratories with large, 
medium, and small sputum specimen volumes. National 
roll-out was completed in December, 2013.
Data collection
In view of the dearth of primary cost data available on 
tuberculosis services in South Africa,18 we collected 
extensive primary data on outcomes, patient events (or 
resource use), and costs. We used this primary data to 
construct a dataset containing individual costs and 
outcomes for every XTEND participant as the basis for 
our analysis.
Because the details of our costing methods, prices, and 
unit costs of each patient event are reported elsewhere,17,19 
we only provide a brief overview in this Article. We used 
primary data collection methods to estimate all costs 
(including human resource costs) at both the site and 
above-site levels. We included all capital and recurrent 
costs at the facility and laboratory (site) level, and the 
above-site level costs incurred by the central laboratory 
services, including quality control and training for both 
Xpert and sputum smear microscopy.17 We collected cost 
data from all 20 XTEND peripheral laboratories and one 
reference laboratory. We measured diagnostic test costs 
at each of these laboratories during two periods (in the 
first 2 months and last 2 months of the XTEND study).
We estimated the cost of drug-sensitive tuberculosis 
treatment from ten XTEND study clinics purposively 
selected to represent the range in number of annual 
primary health-care visits (size of clinic) and geography 
(urban, rural, and peri-urban) of primary health-care 
clinics in South Africa. We primarily used bottom-up 
methods to cost visits, using interviews, facility records, 
Sputum smear microscopy 
group (n=2332)
Xpert group (n=2324)
Total 
cohort cost 
($)
Mean cost per 
cohort member 
($; 95% CI)
Total 
cohort cost 
($)
Mean cost per 
cohort member 
($; 95% CI)
Health service costs
Hospital treatment 24 131 10·35 
(4·08–16·62)
20 765 8·94 
(2·66–15·21)
Health service visits 19 283 8·27 
(6·84–9·70)
24 298 10·46 
(7·00–13·91)
Antibiotics 128 0·06 
(0·05–0·06)
183 0·08 
(0·07–0·08)
Other treatment of symptoms 6418 2·75 
(2·31–3·20)
8398 3·61 
(3·05–4·18)
Sputum smear microscopy (for diagnosis) 20 222 8·67 
(8·62–8·72)
0 0·00
Xpert 0 0·00 56 758 24·42 
(24·30–24·54)
Chest radiograph 1492 0·64 
(0·51–0·77)
1558 0·67 
(0·52–0·82)
Culture 9354 4·01 
(3·65–4·38)
2528 1·09 
(0·90–1·27)
Line probe assay 3182 1·36 
(0·88–1·84)
1408 0·61 
(0·21–1·00)
Drug-susceptibility testing 3759 1·61 
(0·95–2·27)
3222 1·39 
(0·88–1·90)
Subtotal diagnosis 87 969 37·72 
(31·03–44·41)
119 118 51·26 
(43·79–58·72)
Category 1 treatment 42 757 18·33 
(16·15–20·52)
40 409 17·39 
(15·25–19·52)
Category 2 retreatment 8823 3·78 
(2·51–5·06)
3318 1·43 
(0·62–2·24)
Multidrug resistant-tuberculosis treatment 37 263 15·98 
(2·71–29·25)
37 668 16·21 
(2·90–29·52)
Subtotal treatment 88 844 38·10 
(24·02–52·17)
81 396 35·02 
(20·93–49·12)
Subtotal HIV testing and treatment 197 389 84·64 
(78·65–90·64)
191 758 82·51 
(76·62–88·40)
Total health service cost 374 202 160·46 
(143·24–
177·68)
392 271 168·79 
(149·16–
188·42)
Patient incurred cost
Diagnosis 244 520 104·85 
(63·03–146·68)
267 454 115·08 
(70·43–159·74)
Treatment 55 119 23·64 
(20·79–26·48)
46 249 19·90 
(17·30–22·50)
HIV testing and treatment 22 464 9·63 
(9·06–10·20)
20 471 8·81 
(8·27–9·35)
Total patient incurred cost 322 103 138·12 
(95·98–180·27)
334 174 143·79 
(98·30–189·28)
Total cost
Total cost 696 306 298·58 
(246·35–
350·82)
726 445 312·58 
(252·46–
372·70)
Costs are in US$ for 2014.
Table 2: Total and mean costs by study group
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and observations. For multidrug-resistant tuberculosis 
treatment costs, we retrospectively collected patient-level 
and clinic-level cost data from five non-XTEND study 
health facilities: two primary care clinics, one community 
health centre, one local subacute inpatient facility, and a 
central tuberculosis hospital in Cape Town.19 We 
estimated the costs of both centralised and decentralised 
care models. Finally, we sourced HIV costs from a 
systematic review.20 A summary of the provider unit costs 
used is presented in the appendix, together with a list of 
the publications containing further details of the primary 
cost data.
We estimated the direct and indirect costs incurred 
by study participants while accessing care from the 
reported start of tuberculosis symptoms.21,22 In summary, 
three samples of patients were interviewed.21 We con-
secutively subsampled one in three of the patients treated 
at the ten XTEND study clinics selected for health service 
costing and succeeded in enrolling a cohort of 
351 individuals being investigated for tuberculosis, who 
were interviewed at XTEND enrolment and then at follow-
up 6 months later. We interviewed a further cohort of 
168 patients on first-line tuberculosis treatment, who were 
not part of the XTEND cohort (to protect from interview 
overload), at 2 months and 5 months from start of 
treatment. Finally, we interviewed a cross-section of 
134 patients with multidrug-resistant tuberculosis from 
Western Cape.22 All respondents were asked about their 
health-seeking activities, the associated costs, income loss, 
the time cost of carers, and any coping strategies used.
We estimated total costs for the Xpert and the sputum 
smear microscopy groups by multiplying unit or per-event 
costs by the number of health service use events reported 
in the XTEND study cohort. Data on patient events 
(outpatient visits, treatment regimens, and diagnostic 
tests used) were collected from case note abstractions 
(from paper and electronic records) and by self-report 
from the XTEND participant follow-up interviews (done 
with all XTEND participants). Where discrepancies 
between data sources were found, a set of decision rules 
were developed and applied on the basis of plausibility 
and consistency between data.
Outcomes
We estimated mean total costs and cost per DALY 
averted. DALYs averted were the main measure of 
incremental outcome. We used deaths reported from the 
XTEND study (appendix) to estimate years of life lost. 
The XTEND study’s primary outcome was mortality 
among participants investigated for tuberculosis, 
measured 6 months after enrolment. The XTEND study 
found no evidence of a difference in mortality risk 
(91 [4%] of 2324 vs 116 [5%] of 2332; adjusted risk 
ratio 1·10, 95% CI 0·75–1·62).11 We estimated the years 
lived with disability of its participants using the number 
of days with tuberculosis symptoms, assuming 
symptoms either stopped 2 weeks into treatment, 
continued to death, or stopped within 2 weeks of not 
returning to care. We applied disability weights used in 
the Global Burden of Disease 2010.23 For people living 
with HIV/AIDS on antiretroviral therapy for HIV, we 
applied the tuberculosis only disability weight.23 We 
estimated all DALYs averted using a 3% discount rate and 
no age weighting.
Statistical analysis
To complete our patient-level dataset, we first had to 
address the missing data by design (due to subsampling) 
for the patient-incurred costs. We used two methods: 
applying mean per-event costs from our subsample 
and applying multiple imputation to assign per-event 
costs from our subsample of 351 to the total sample of 
4656 XTEND participants.21 The multiple imputation 
covariates included sex (binary), number of years at 
school (ordinal), self-reported HIV status (categorical), 
initial tuberculosis test result (binary), geographical 
location (binary: urban or rural), income (categorical), 
number of days with at least one symptom (continuous), 
anyone else in household with a regular job (binary), 
household socioeconomic status (categorical: derived 
through principal component analysis), number of 
health-care visits (continuous), country of birth 
(categorical), age (continuous), province (categorical), 
and distance from residence to clinic (ordinal). In view of 
the high number of zero observations in our subsample 
for some per-event costs, we applied a two-part model, 
which first predicts non-zero costs for each type of 
Simple imputation dataset* Multiple imputation dataset*
β coefficient† (95% CI) p value β coefficient† (95% CI) p value
Incremental difference in total costs per cohort member
Xpert vs sputum smear 
microscopy
23·34 (–22·86 to 69·55) 0·303 29·63 (–48·98 to 108·24) 0·439
Constant –11·52 (–44·20 to 21·15) 0·468 –14·56 (–70·14 to 41·03) 0·589
Incremental difference in patient incurred costs per cohort member
Xpert vs sputum smear 
microscopy
9·30 (–23·33 to 41·94) 0·557 15·59 (–50·29 to 81·47) 0·625
Constant –4·61 (–27·68 to 18·47) 0·680 –7·64 (–54·23 to 38·95) 0·734
Incremental difference in provider costs per cohort member
Xpert vs sputum smear 
microscopy
14·04 (–11·91 to 39·99) 0·271 14·04 (–11·91 to 39·99) 0·271
Constant –6·92 (–25·27 to 11·44) 0·439 –6·92 (–25·27 to 11·44) 0·439
Incremental difference in provider costs (diagnostic test only) per cohort member
Xpert vs sputum smear 
microscopy
14·65 (2·30 to 27·01) 0·023 14·65 (2·30 to 27·01) 0·023
Constant –7·31 (–16·04 to 1·43) 0·096 –7·31 (–16·04 to 1·43) 0·096
Costs are in US$ for 2014. *Simple imputation using means of patient costs from subsample. Both datasets adjusted 
for HIV status, socioeconomic status quintiles (based on principal component analysis), ethnicity, education, marital 
status, age group, sex, province, body-mass index group, and number of symptoms. †We have the general form of a 
regression equation: Y=constant + (βX). Where Y is the difference in costs between the Xpert and sputum smear 
microscopy groups (ie the incremental cost) and X is a binary variable that represents the groups (Xpert=1 and sputum 
smear microscopy=0). For example, in the case of total costs, the incremental cost between Xpert and sputum smear 
microscopy is –11·52 + 23·34=11·82.
Table 3: Mean incremental costs of Xpert versus sputum smear microscopy per cohort member
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patient event, and then predicts the level of costs for 
events with a non-zero cost.
The cost and cost-effectiveness analyses reflected the 
clustered design and baseline imbalance between study 
groups.24 For both analyses, we selected a two-stage 
cluster-level analysis with non-parametric two-stage boot-
strapping.25 The two-stage bootstrapping algorithm 
performs resampling with replacement in two stages. In 
the first stage, it resamples clusters and in the second 
stage it resamples individuals within clusters. A 
shrinkage estimator is used to correct for potential 
overestimation of variance. Bootstrap datasets are then 
constructed, combining the resampled shrunken cluster 
means with resampled individual-level residuals.
For the cost analysis, we applied a multiple ordinary 
least square regression model with robust standard 
errors using 200 bootstrap replications and adjusting 
for HIV status, socioeconomic status, ethnicity, 
education, marital status, age group, sex, province, 
body-mass index group, and number of symptoms. We 
calculated the predicted cost for each patient and 
subsequently collapsed the data across cluster and 
calculated the residual (difference of observed and 
predicted) costs for each cluster. In the second stage, we 
ran an ordinary least squares regression analysis at the 
cluster level to assess differences in costs between Xpert 
and sputum smear microscopy groups using the 
residuals as the dependent variable. We used this 
method to estimate incremental costs between the 
two study groups.
For our cost-effectiveness analysis, we sampled (with 
two-stage bootstrapping) from adjusted costs (produced 
in the cost analysis) and adjusted deaths (using the 
adjusted analysis on outcomes as outlined in the main 
trial paper; appendix)24 to estimate cost-effectiveness 
ratios per death and DALYs averted, running 
10 000 replications (appendix). We present the un-
certainty around our incremental cost-effectiveness 
ratios with cost-effectiveness planes and acceptability 
curves and apply a one-way sensitivity analysis around 
0% and 3% discount rates. All costs are presented in 
2014 US$.
We used Stata 14.1 for the statistical analysis and 
prepared the dataset linking events and costs in 
Excel 2007.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
We stratified summary data of patient events by 
subgroups of participants: participants with an initial 
positive result; participants with an initial negative 
result, with no subsequent diagnostic test; and 
participants with an initial negative result, but received 
follow-up diagnostic tests (table 1). Although the Xpert 
group had more initial positive tuberculosis results 
than sputum smear microscopy (200 [7%] of 
2324 patients vs 174 [7%] of 2332), fewer patients had 
Figure 1: Cost-effectiveness planes of Xpert versus sputum smear microscopy
Cost-effectivness planes showing the results of two different models of non-parametric two-stage bootstrapping 
using 10 000 replications to produce incremental costs per DALYs averted for Xpert versus sputum smear 
microscopy, with 3% (A) and 0% (B) discount rates. The x-axis represents the difference in DALYs averted, and the 
y-axis represents the difference in costs for the imputed data using 10 000 replications. Each point in the 
scatterplot represents one bootstrap iteration. Costs are in 2014 US$. DALY=disability-adjusted life-year.
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follow-up tests (211 [9%] of 2324 patients vs 441 [19%] of 
2332). Total treatment initiations were lower in the 
Xpert group than the sputum smear microscopy group 
(250 events in 2324 patients vs 291 events in 
2332 patients). This included lower numbers of patients 
initiated on a retreatment regimen (12 events in 
2324 patients vs 34 events in 2332 patients). The total 
number of hospital days was higher in the Xpert group 
(546 days vs 506 days), primarily incurred by participants 
with multidrug-resistant tuberculosis. The total 
number of cultures done in the Xpert group was also 
lower (167 tests vs 497 tests), but the total number of 
antibiotic courses provided was higher (659 vs 462). The 
total number of HIV tests done was similar in both 
groups, as was the total number of patients starting 
antiretroviral therapy.
Applying the unit costs to patient events, we found the 
mean total cost per participant incurred was US$312·58 
(95% CI 252·46–372·70) in the Xpert group and $298·58 
(246·35–350·82) in the sputum smear microscopy group 
(table 2). The mean health service (provider) cost per 
participant was $168·79 (149·16–188·42) for Xpert and 
$160·46 (143·24–177·68) for the sputum smear 
microscopy. We found that Xpert increases the cost of 
initial diagnostic tests, but this was mitigated by a 
decrease in the costs of follow-on diagnostics and 
treatment. A small difference was reported in total mean 
patient-incurred costs between the Xpert and the sputum 
smear microscopy groups ($143·79 vs $138·12). After 
adjustment for baseline imbalance between the 
two groups, we found no significant difference in costs 
between Xpert and the sputum smear microscopy groups 
(table 3). Only health service diagnostic costs were found 
to differ significantly between the two groups, with Xpert 
costs being higher than sputum smear microscopy 
(p=0·023).
The mean incremental costs and mean incremental 
effect of Xpert compared with sputum smear 
microscopy fall into the upper left quadrant of the cost-
effectiveness plane (figure 1, table 4). This was the 
same if we used a 0% or 3% discount rate. After 
application of a wide range of willingness to pay 
thresholds, our results suggest that there is less than 
3% probability that Xpert is cost-effective in this 
population (figure 2).
Discussion
We found that the Xpert roll-out in South Africa, for a 
population of presumptive drug-susceptible tuberculosis 
participants, did not decrease or increase costs of 
tuberculosis investigation, diagnosis, and treatment (in 
the period from symptoms to 6 months after initial 
investigation), and, in this sense, can be described as 
cost-neutral. The additional cost of Xpert equipment and 
tests was mitigated by a reduction in costs elsewhere in 
the tuberculosis cascade of care. In the Xpert group, 
fewer people started treatment on an empirical basis and 
Simple imputation dataset* Multiple imputation dataset†
Deaths averted DALYs averted 
(0%)
DALYs averted 
(3%)
Deaths averted DALYs averted 
(0%)
DALYs averted 
(3%)
Incremental difference in outcomes 
(95% CI)
–0·011 
(–0·028 to 0·01)
–0·13 
(–0·68 to 0·42)
–0·09 
(–0·42 to 0·26)
–0·011 
(–0·028 to 0·01)
–0·13 
(–0·68 to 0·42)
–0·09 
(–0·42 to 0·26)
Mean ICER‡ –1148 –92 –129 –1534 –123 –172
Costs are in US$ for 2014. DALY=disability-adjusted life-year. ICER=incremental cost-effectiveness ratio. *Incremental difference in cost $12·25 (95% CI –47·10 to 69·18). 
†Incremental difference in cost $16·36 (95% CI –70·07 to 104·58). ‡ICERs are negative and therefore cannot be used to assess cost-effectiveness; see figures 1 and 2.
Table 4: Incremental costs and outcomes of Xpert versus sputum smear microscopy
Figure 2: Cost-effectiveness acceptability curves of Xpert versus sputum smear microscopy
The cost-effectiveness acceptability curves were generated by running 10 000 replications. The probability of Xpert 
being cost-effective was examined at different WTP thresholds, with 3% (A) and 0% (B) discount rates. Costs are in 
2014 US$. WTP=willingness to pay. DALY=disability-adjusted life-year.
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began retreatment. However, Xpert showed higher 
diagnostic costs than sputum smear microscopy, 
including higher levels of prescriptions of other 
antibiotics and additional symptom seeking visits, 
possibly due to lower levels of empirical treatment for 
tuberculosis. Combining cost neutrality with the absence 
of any significant mortality effect, we found that the 
introduction of Xpert did not improve the cost-
effectiveness of drug-susceptible tuberculosis diagnosis 
and treatment in South Africa during the early stages of 
the national Xpert roll-out.
This finding differs from modelled predictions of the 
cost-effectiveness of Xpert introduction. Our previous 
model,5 and many others, assumed that for people 
investigated for tuberculosis with an initial negative 
tuberculosis test result the follow-on diagnostic pathway 
would either be highly sensitive, but with low specificity 
(for example, a chest radiography or high levels of 
empirical treatment) or use a diagnostic such as culture, 
but limited to a small proportion of patients.5 Sensitivity 
and specificity of this pathway were therefore assumed to 
be negatively correlated with one another.5 By reducing 
the numbers of false-negative tuberculosis cases moving 
along this diagnostic pathway, Xpert would either reduce 
overtreatment or prevent mortality.
The TB-NEAT trial26 found that Xpert did not affect 
mortality and could replace, but not reduce, empirical 
treatment. The absence of the anticipated reduction in 
empirical treatment might have been partly attributable 
to providers becoming more aware of the limitations of 
tuberculosis diagnostics generally.27 Like wise, XTEND 
found no effect on mortality, and a reduction in follow-up 
along the initial test negative pathway during roll-out.11 In 
a setting with the momentum of a national roll-out, these 
reductions in follow-up tests could be attributable to 
clinicians overly trusting Xpert results, as the new 
technology is promoted. This explanation is supported by 
the findings of an XTEND substudy28 examining the 
pathways of participants with initial negative results, 
which found much lower levels of algorithm adherence 
and HIV testing among participants with an initial Xpert 
test compared with participants with sputum smear 
microscopy.
Additionally, both of the study groups in XTEND had 
high levels of loss to follow-up and moderate levels of 
antiretroviral therapy coverage, which potentially 
mitigated any effect on outcomes that would result from 
a correct tuberculosis diagnosis.11 Similar findings were 
seen in Brazil, where high levels of loss to follow-up 
undermined any potential increment effect of Xpert.29 
Therefore, in the case of XTEND, TB-NEAT, and the 
Brazil study, the cost and cost-effectiveness of Xpert were 
fundamentally affected by both the existing standard-of-
care comparator, and the way in which Xpert was 
implemented, and the adherence along both the 
tuberculosis and HIV diagnostic and treatment pathways, 
rather than the performance of the technology itself.
Prior to WHO guideline recommendations and roll-
out, economic evaluations of tuberculosis diagnostics 
were not able to access data to adequately parameterise 
standard-of-care clinical practice, or the algorithms used, 
and were not able to predict how these practices might 
change with different approaches to implementation. The 
extensive primary data collection permitted by a phased 
approach to roll-out enabled us to correct our initial 
estimates. More broadly, our research, together with the 
emerging research on malaria diagnostics, highlights the 
importance of post-hoc real-world economic analyses of 
new technologies to validate initial predictions.16 
Additionally, our findings provide an example to support 
the broader calls for model-based economic evaluations 
to formally consider uncertainty (and the additional costs) 
of implementation of new diagnostic technologies in 
general.30
Our study has several limitations. First, the methods to 
account for clustering and imbalance can generate 
narrower CIs than with other more complex and time-
consuming methods such as multilevel modelling, even 
if they produce unbiased estimates of the mean 
incremental cost-effectiveness ratio.24 This means that 
our results can seem more certain than is the case. 
However, considering our probability of cost-
effectiveness is extremely low, this underestimation of 
uncertainty is unlikely to affect our conclusion. Second, 
although we imputed patient-incurred costs, and 
captured some uncertainty in this imputation, our 
sample of primary cost data was not powered to detect 
true differences in patient-incurred costs between Xpert 
and sputum smear microscopy. Third, we had to make 
crude assumptions about duration of symptoms to 
estimate years lived with disability. However, the level of 
years lived with disability is dwarfed by years of life lost 
in the DALY calculations.
Fourth, we limited the timeframe of our assessment to 
a within-trial period. This potentially excludes potential 
benefits for participants with multidrug-resistant 
tuberculosis and future relapses. We take this approach 
because little real-world evidence exists to show an effect of 
Xpert on the costs or outcomes of people with multidrug-
resistant tuberculosis or on tuberculosis relapses in 
South Africa. As with the diag nosis of drug-susceptible 
tuberculosis, outcomes are likely to also be affected by the 
follow-on treatment pathway. However, Xpert might 
conceivably have a positive effect on multidrug-resistant 
tuberculosis outcomes and transmission through the 
reduction of time to treatment. Conversely, some additional 
costs might also occur due to people with multidrug-
resistant tuberculosis being placed on treatment without 
comprehensive drug susceptibility testing. However, not 
enough data exist to investigate either hypothesis. We 
therefore limit our findings and conclusions to people 
with drug-susceptible tuberculosis.
Fifth, generally within-trial economic evaluations 
might be seen as limited because they might not 
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represent the full range of evidence available (unlike 
modelled evaluation, which involves the synthesis of all 
data). However, our study is a multicentre cluster 
randomised study of 40 sites in South Africa in addition 
to being the only robust and comprehensive source of 
real-world cost and outcomes data available during the 
period of the early Xpert roll-out in South Africa. That 
said, even pragmatic trials do not fully capture real-
world practice. Routine data systems could be an 
additional data source if of sufficient quality and 
appropriately analysed. Analysts in other settings with 
less data scarcity should continue to consider all relevant 
evidence and continue to do model-based economic 
evaluations of tuberculosis diagnostics as the 
preferential approach.
Although our results suggest that South Africa might 
not have made a sound investment in Xpert initially, this 
does not mean that Xpert will not be cost-effective in 
other settings, or in South Africa in the future. Our 
results instead suggest that policy makers need to 
consider the context that Xpert (and other tuberculosis 
diagnostics) are placed in before providing large-scale 
investment. Our research highlights the need to 
simultaneously consider and define complementary 
interventions to optimise the Xpert-based tuberculosis 
diagnostic and treatment pathway. Finally, our study 
shows the importance for global policy makers and 
funders (and the analysts supporting them) to consider 
the uncertainty caused by implementation constraints 
when making recommendations for guidelines and 
investing in new tuberculosis diagnostics.
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